Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Yeah, great. So we talked a little bit about this distinction between partial and functional cure at the conference today. I'm wondering if you can talk a little bit more about this idea of functional cure relative to partial cure rates. Do you believe that functional cure rates will still be the standard by which Phase 2 and Phase 3 programs will be held to? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 25, 2023 / 1:30PM, DTIL.OQ - Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual)

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Yeah, interesting. So can you talk about the distinction between cccDNA and integrated DNA and why it's important to address both sources of HBV RNAs?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Got it. That's helpful. And can you talk about PBGENE-HBV, specifically the mechanism of action? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 25, 2023 / 1:30PM, DTIL.OQ - Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual)

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : And how is PBGENE-HBV delivered to liver tissue and which cells is it targeting? And why has Precision decided on this targeting mechanism in these liver cell types?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Yeah, that's interesting. And how confident are you that PBGENE-HBV should avoid viral resistance? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 25, 2023 / 1:30PM, DTIL.OQ - Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual)

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Right. Interesting. And is there any risk to removing integrated DNA from human hepatocytes?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : Right, that's helpful. That makes sense. And then can you talk about the preclinical data, what it's demonstrated a bit more about how confident you are that this data can then translate to humans?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : I guess just as we're thinking about getting the IND filed and what that first in-human study might look like, do you have an idea of what that trial design could look like and when you may have details to share with investors?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : So earlier, we were talking about these distinctions between some of these endpoints, and there was lengthy discussions around endpoints last year at AASLD and a bit more into EASL this year. So I'm curious, as you're thinking about how to set up this trial, what learnings have emerged? We've also heard about -- there were many, many programs five years ago, and now, there are fewer programs, but surely there's been some learnings that have emerged. What do you think has been some of the key takeaways that you could take forward to your program?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : I think we may have lost Cassie. Now, we can hear -- now, we can see you and hear you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 25, 2023 / 1:30PM, DTIL.OQ - Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual)

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : It's okay. No problem.

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : No, I think maybe if you could maybe go through the answer from the start just because I think it just might be easier.

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : And then just in terms of the baseline characteristics of patients, would you be looking to segment by HB surface antigen at baseline, or how would you think about that in this first study that you would run?

Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst : And understanding we're well ahead of the first in-human trial being conducted, I'm just curious how you're thinking about -- with chronic HBV appearing to have this immune-suppressive mechanism, how does PBGENE-HBV approach address what appears to be this immune system exhaustion? And is there a potential to combine it with other modalities? And if so, what would those be?